Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol. 2008;3:471–80.
Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, Kaplan B. Early conversion to belatacept in kidney transplant recipients with low glomerular filtration rate. Transplantation. 2018;102(3):478–83.
Abraham WT, Smith SA. Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol. 2013;10:98–110.
Abramowicz D, Cochat P, Claas FH, Heemann U, Pascual J, Dudley C, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015;30:1790–7.
Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694–705.
Addis RC, Epstein JA. Induced regeneration--the progress and promise of direct reprogramming for heart repair. Nat Med. 2013;19:829–36.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.
Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis. 2014;6:1120–8.
American Society of Transplantation Infectious Diseases Guidelines 3rd Edition. March 2013; 13(s4):1–371. Available from: http://onlinelibrary.wiley.com/doi/10.1111/ajt.2013.13.issue-s4/issuetoc (accessed June 2017).
Andrews PA; Standards Committee of the British Transplantation Society. Summary of the British Transplantation Society guidelines for management of the failing kidney transplant. Transplantation. 2014;98:1130–3.
Angeli P, Bezinover D, Biancofiore G, Bienholz A, Findlay J, Paugam Burtz C, et al. Acute kidney injury in liver transplant candidates: a position paper on behalf of the Liver Intensive Care Group of Europe. Minerva Anestesiol. 2017;83:88–101.
Assfalg V, Hüser N, van Meel M, Haller B, Rahmel A, de Boer J, et al. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrol Dial Transplant. 2016;31:1515–22.
Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol. 2006;1:1080–9.
Bagshaw SM, Lamontagne F, Joannidis M, Wald R. When to start renal replacement therapy in critically ill patients with acute kidney injury: comment on Living kidney donation and ELAIN. Crit Care. 2016;20:245.
Ballios BG, Weisbrod M, Chan CC, Borovik A, Schiff JR, Tinckam KJ, et al. Systemic immunosuppression in limbal stem cell transplantation: best practices and future challenges. Can J Ophthalmol. 2018;53:314–23.
Bamgbola O. A Critical Review of Steroid Immunotherapy in Kidney Transplantation. Int J Immunol Immunother. 2015;2:1.
Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, et al. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Transpl Infect Dis. 2018;20:e12919.
Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: Consistent and equitable? Transplantation. 2012;94:703–13.
Bathla L, Langnas A. Chapter 63. Multivisceral Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 697–702. 2014; Wiley Online Library.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019;00:1–17.
Bessede T, Droupy S, Hammoudi Y, Bedretdinova D, Durrbach A, Charpentier B, et al. Surgical prevention and management of vascular complications of kidney transplantation. Transpl Int. 2012;25:994–1001.
Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53:1570–9.
Bhat M, Al-Busafi S, Deschênes M, Ghali P. Care of the liver transplant patient. Can J Gastroenterol Hepatol. 2014;28:213–9.
Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol. 2007;18:3031–41.
Bownik H, Saab S. Health-related quality of life after liver transplantation for adult recipients. Liver Transpl. 2009;15 Suppl 2:S42–9.
Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11:2453–62.
Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2018; [Epub ahead of print].
British Transplantation Society, 2015. The prevention and management of CMV disease after solid organ transplantation. Third edition. July 2015. Available from: https://bts.org.uk/wp-content/uploads/2016/09/14_BTS_CMV_3RDE-1.pdf (accessed July 2019).
British Transplantation Society/The Renal Association, 2018. Guidelines for living donor kidney transplantation. Fourth Edition. March 2018. Available at: https://bts.org.uk/wp-content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf accessed July 2019.
British Transplantation Society (Working Party), 2017. Kidney & pancreas transplantation in patients with HIV. Second edition. March 2015 (minor revision, Jan 2017). Available from: https://bts.org.uk/wp-content/uploads/2017/04/02_BTS_Kidney_Pancreas_HIV.pdf (accessed July 2019).
British Transplantation Society and British Association for the Study of the Liver (Joint Working Party), 2015. Living Donor Liver Transplantation. July 2015. Available from: https://bts.org.uk/wp-content/uploads/2016/09/03_BTS_LivingDonorLiver-1.pdf (accessed July 2019).
Broumand B. The global registry: hope for the future. Exp Clin Transplant. 2015;13 Suppl 1:4–8.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, et al. Five-year outcomes in kidney transplant patients converted from ciclosporin to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119–28.
Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens. 2011;20:610–5.
Chandrashekaran S, Crow Pharm SA, Shah SZ, Arendt Pharm CJ, Kennedy CC. Immunosuppression for lung transplantation: current and future. Curr Transplant Rep. 2018;5:212–19.
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013;3:a015677.
Charlton MR. Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013;19(8):787–9.
Charlton MR. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014;18:717–30.
Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101(12):2873–82.
Chen JM, Canter CE, Hsu DT, Kindel SJ, Law YM, McKeever JE, et al. Current topics and controversies in pediatric heart transplantation: Proceedings of the Pediatric Heart Transplantation Summit 2017. World J Pediatr Congenit Heart Surg. 2018 Sep;9:575–81.
Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27(10):1039–49.
Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013;95:933–42.
Clajus C, Hanke N, Gottlieb J, Stadler M, Weismüller TJ, Strassburg CP, et al. Renal comorbidity after solid organ and stem cell transplantation. Am J Transplant. 2012;12:1691–9.
Collaborative Transplant Study (CTS), 2016.; Available from: http://www.ctstransplant.org/ (accessed June 2017).
Collett D, Mumford L, Banner NR, Neuberger J, Watson CJE. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010; 10:1889–96.
Cooper JE, Christians U, Wiseman AC. Everolimus in kidney transplantation. Transpl Res Risk Management. 2011;3:97–112.
Copelan E.A. (2006). Hematopoietic stem-cell transplantation. New Engl J Med. 2006;354:1813–26.
Colvin M, Smith JM, Skeans MA, Edwards LB, Uccellini K, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Heart. Am J Transplant. 2017;17 Suppl 1:286-356.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.
Craig JM, Lee S, Vlahakes GL, Madsen JC. Chapter 58. Heart Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 657–66. 2014; Wiley Online Library.
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–28.
Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low ciclosporin in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010;23:1084–93.
Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol. 2005;16:2098–110.
Davis RD, Hartwig M. Chapter 59. Lung Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 667–73. 2014; Wiley Online Library.
De Lucena DD, Rangel ÉB. Glucocorticoids use in kidney transplant setting. Expert Opin Drug Metab Toxicol. 2018;14(10):1023-41.
Delanaye P, Weekers L, Dubois BE, Cavalier E, Detry O, Squifflet JP, et al. Outcome of the living kidney donor. Nephrol Dial Transplant. 2012;27:41–50.
Desai R, Neuberger J. Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol. 2014;20:6170–9.
De Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girao CM, Campos EF, Esmeraldo RM. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial. Transpl Int. 2018:12:1345–56.
De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15:1262–9.
De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol. 2017b;31(2):199–209.
De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of Everolimus in liver transplantation: recommendations from a working group. Transplantation. 2017a;101:239–51.
De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008–20.
Diaz G, O'Connor M. Cardiovascular and renal complications in patients receiving a solid-organ transplant. Curr Opin Crit Care. 2011;17:382–9.
Dominguez-Gil B, Delmonico FL, Shaheen FA, Matesanz R, O'Connor K, Minina M, et al. The critical pathway for deceased donation: reportable uniformity in the approach to deceased donation. Transplant Int. 2011;24:373–8.
Dudley C, Harden P. Assessment of the Potential Kidney Transplant Recipient. 5th Edition. Final Version (12 January 2011). The Renal Association, 2011. Available from: https://bts.org.uk/wp-content/uploads/2016/09/10_RA_KidneyRecipient-1.pdf (accessed July 2019).
Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the Mammalian Target of Rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives. Cancers (Basel). 2011;3:2478–500.
Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, et al. mTOR inhibitors in pediatric liver transplant recipients. Clin Res Hepatol Gastroenterol. 2018 Dec 6. (Epub ahead of print.)
Dumortier J, Dharancy S, Calmus Y, Duvoux C, Durand F, Salamé E, et al. Use of everolimus in liver transplantation: The French experience. Transplant Rev (Orlando). 2016;30(3):161–70.
Dürr M, Lachmann N, Zukunft B, Schmidt D, Budde K, Brakemeier S. Late conversion to belatacept after kidney transplantation: outcome and prognostic factors. Transplant Proc. 2017;49(8):1747–56.e1.
Einecke G, Reeve J, Halloran PF. Hyalinosis lesions in renal transplant biopsies: time-dependent complexity of interpretation. Am J Transplant. 2017;17:1346–57.
Eisenberger U, Budde K, Lehner F, Sommerer C, Reinke P, Witzke O, et al. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrol. 2018;19(1):154.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med. 2007;357: 2562–75.
Elfadawy N1, Yamada M2, Sarabu N3.Management of BK polyomavirus infection in kidney and kidney-pancreas transplant recipients: a review article. Infect Dis Clin North Am. 2018;32:599─613.
EMA. Simulect, basiliximab. October 2009a; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000207/human_med_001054.jsp&mid=WC0b01ac058001d124 (accessed July 2019).
EMA. Zenapax, daclizumab. February 2009b; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000198/human_med_001175.jsp&mid=WC0b01ac058001d124 (accessed July 2019).
European Association for the Study of the Liver (EASL). The burden of liver disease in Europe. 2013; Available from: www.easl.eu/medias/EASLimg/Discover/EU/54ae845caec619f_file.pdf (accessed July 2019).
European Commission. Organs. 2016; Available from: http://ec.europa.eu/health/blood_tissues_organs/organs/index_en.htm (accessed July 2019).
Eurotransplant. Annual Report 2014. 4: Eurotransplant: donation, waiting lists and transplants. Available from: http://www.eurotransplant.org/cms/mediaobject.php?file=ar_2014.pdf (accessed June 2017).
Finkbeiner SR, Freeman JJ, Wieck MM, El-Nachef W, Altheim CH, Tsai YH, et al. Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. Biol Open. 2015;4:1462–72.
Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. Am J Transplant. 2012;12:1855–65.
Fishbein T. Chapter 62. Intestinal Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 691–6. 2014; Wiley Online Library.
Fischer SA, Lu K; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):9–21.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simnone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus. Follow-up results from a randomized, multicenter study. Transplantation. 2015;99(7):1455–62.
Fisher MB, Mauck RL. Tissue engineering and regenerative medicine: recent innovations and the transition to translation. Tissue Eng Part B Rev. 2013;19:1–13.
Fishman JA; AST Infectious Diseases Community of Practice. Introduction: infection in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S3–6.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1–15.
Fredericks EM, Zelikovsky N, Aujoulat I, Hames A, Wray J. Post-transplant adjustment--the later years. Pediatr Transplant. 2014;18:675–88.
Friend PJ. Alemtuzumab induction therapy in solid organ transplantation. Transplant Res. 2013;2:S5.
Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016;375:122–33.
Gentile S, Beauger D, Speyer E, Jouve E, Dussol B, Jacquelinet C, et al. Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France. Health Qual Life Outcomes. 2013;11:88.
Gibbons N, Nicol D. Surgical techniques in living donor nephrectomy. Nephrology (Carlton). 2010;15:S88–95.
Girerd S, Schikowski J, Girerd N, Duarte K, Busby H, Gambier N, et al. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014. BMC Nephrol. 2018;19(1):232.
Global Observatory on Donation and Transplantation. Organ donation and transplant activities, 2013. Available from: http://www.transplant-observatory.org/report-2013/ (accessed June 2017).
Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V. Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation: a meta-analysis of randomized controlled trials. Transplantation. 2016;100(3):621–9.
Gondos A, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013;95:267–74.
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374:411–21.
Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant. 2013;27:140–7.
Green M, Michaels MG. Infections in Pediatric Solid Organ Transplant Recipients. J Pediatric Infect Dis Soc. 2012;1:144–51.
Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8:6–16.
Gruessner RW, Gruessner AC. Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry. Am J Transplant. 2016;16:688–93.
Hariharan K, Kurtz A, Schmidt-Ott KM. Assembling Kidney Tissues from Cells: The Long Road from Organoids to Organs. Front Cell Dev Biol. 2015;3:70.
Hart A, Gustafson SK, Skeans MA, Stock P, Stewart D, Kasiske BL, et al. OPTN/SRTR 2015 Annual Data Report: Early effects of the new kidney allocation system. Am J Transplant. 2017;17 Suppl 1:543–564.
Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013;3:a015487.
Health Quality Ontario. Limbal stem cell transplantation: an evidence-based analysis. Ont Health Technol Assess Ser. 2008;8:1–58.
Health Quality Ontario. Pancreas islet transplantation for patients with type 1 Diabetes Mellitus: A Clinical Evidence Review. Ont Health Technol Assess Ser. 2015;15:1–84.
Health Resources and Services Administration: Blood Cell Transplant. 2015; Transplant Activity Report. Available from: http://bloodcell.transplant.hrsa.gov/research/transplant_data/transplant_activity_report/index.html (accessed April 2016).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. 2016a; Available from: http://optn.transplant.hrsa.gov/ (accessed April 2016).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. Evolution of liver allocation and distribution. 2016b; Available from: https://optn.transplant.hrsa.gov/governance/policy-initiatives/liver-timeline/ (accessed June 2017).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. Kidney Allocation System. 2016c.; Available from: https://optn.transplant.hrsa.gov/learn/professional-education/kidney-allocation-system/ (accessed June 2017).
Heemann U, Renders L. State of living kidney donation in Europe. Nephrol Dial Transplant. 2012;27:2166–70.
Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017;1:CD004759.
Hollisaaz MT, Aghanassir M, Lorgard-Dezfuli-Nezad M, Assari S, Hafezie R, Ebrahiminia M. Medical comorbidities after renal transplantation. Transplant Proc. 2007;39:1048–50.